TQD3524

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaMulti-resistant Gram-negative Bacteria Cause Infection

Phase 1

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

CompletedNCT06522945

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Multi-resistant Gram-negative Bacteria Cause Infection

Start: 2024-07-24End: 2025-12-18Updated: 2026-01-09

Phase 2

Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria

RecruitingNCT07512596

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia

Start: 2026-07-21End: 2027-07-01Target: 48Updated: 2026-09-04